Direct answer. Coronary stenting (PCI) opens a narrowed artery from inside using a catheter-based procedure; bypass surgery (CABG) creates another route for blood around an obstruction. Neither is automatically the right option for every person, and neither cures the underlying coronary disease. The decision considers the artery findings, treatment goal, overall health and procedure risks. Emergency heart-attack care is a different decision from a planned discussion about stable symptoms. Confidence is high in these distinctions; no universal independent winner is established here. NHS PCI overview, October 4, 2022, review overdue; NHS CABG clinical role and ongoing disease, July 3, 2025.
- PCI treats an artery from inside; CABG uses graft vessels to bypass an obstruction.
- A planned stable-symptom decision differs from urgent heart-attack treatment.
- The artery pattern, heart function and other illnesses matter more than the label “less invasive.”
- Medicines and coronary risk-factor care continue after a procedure.
- New concerning chest pain, stroke symptoms, major bleeding or serious deterioration require urgent help.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| How do the procedures differ? | Public mechanism education | PCI opens from within; CABG creates a graft route around an obstruction. |
| Is PCI always better because the incision is smaller? | Clinical assessment framework | No universal comparative verdict follows from access size. |
| Does CABG cure coronary disease? | NHS clinical context | No. Ongoing medicine and risk-factor care remain relevant. |
| Can all stable and emergency studies be combined? | Population and treatment-goal boundary | No. Clinical circumstances and outcomes differ. |
| Can a supplement replace revascularization? | Human-evidence boundary | No financially screened replacement regimen is established. |
Confidence is high in the procedure mechanisms, need for a clinical choice and urgent symptom assessment; expected personal benefits and risks require the heart team. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What PCI and coronary bypass surgery mean
PCI means percutaneous coronary intervention. In a typical angioplasty/stent procedure, an arterial catheter guides equipment to a narrowed coronary artery, a balloon opens the treated area and a stent provides a scaffold. The access point may be the wrist or groin. An angiogram that shows the arteries is a diagnostic step; it does not mean a stent must automatically be inserted. NHS PCI mechanism, October 4, 2022, selected context.
CABG means coronary artery bypass grafting, also called heart bypass surgery. A surgeon uses suitable blood vessels from elsewhere in the body to create a new route around diseased sections. A bypass is a route change, not an operation to extract all arterial plaque. NHS CABG definition, July 3, 2025.
Both address a coronary blood-flow problem. The relevant discussion must identify whether the aim is symptom management, another clinical outcome or emergency treatment, and what the alternatives are.
Stents, grafts and surgical approaches
A stent stays in the treated artery as a scaffold. Stent technologies and accompanying medicines need a current procedure-specific discussion. Older general pages describing bare-metal versus drug-eluting selection thresholds or a fixed antiplatelet schedule are not used as a2026 decision rule here. NHS PCI mechanism, October 4, 2022, selected context.
In CABG, arteries or veins can be used as grafts. The number and arrangement depend on the planned operation. “Double” or “triple” bypass describes grafting, not a simple ranking of disease severity or a guarantee about the result. NHS CABG definition, July 3, 2025.
Traditional surgery commonly involves a chest incision and may use a heart–lung bypass machine. Selected approaches may operate off-pump or through smaller incisions. Their suitability depends on the anatomy, health and surgical expertise; a technique label does not establish a universal safety advantage. NHS CABG operation context, July 3, 2025; media September 2026; NHLBI CABG technique and risks, March 24, 2022.
How clinicians compare PCI, CABG and medicines
The heart team can consider the distribution and complexity of narrowed arteries, including whether several vessels or the left main artery are involved, alongside overall health and other conditions. Diabetes, heart function or other illnesses are parts of a wider assessment, not standalone instructions that everyone with that feature must have CABG. NHLBI selected CABG assessment framework, August 28, 2024.
Medicines may be part of the options discussion and remain important after an intervention. In planned care, ask whether symptoms have been adequately assessed, what benefit is expected and why PCI or CABG is recommended in the actual artery pattern. NHS CABG clinical role and ongoing disease, July 3, 2025.
Emergency heart-attack care has urgent treatment considerations that differ from an elective consultation for stable angina. Do not use a stable-symptom study or an internet comparison to delay emergency treatment. The guide does not provide a home algorithm for choosing PCI, CABG or clot-dissolving treatment. NHS PCI overview, October 4, 2022, review overdue.
Ask whether the cardiology and surgical opinions agree, how the options compare for the outcomes relevant to you, and what happens if treatment is deferred. An opportunity to discuss preferences includes recovery demands, medicine requirements and uncertainty—not simply choosing the smaller incision.
The original comparative trial chains were not financially cleared here. There is no universal independently proven winner, survival percentage or repeat-procedure rate. Public educational descriptions are used as clinical context, not as a route to adopt sponsored outcome claims.
Ongoing coronary care, supplements and rehabilitation
Neither a stent nor bypass cures the underlying coronary disease. Continue the agreed medicine and risk-factor plan, including appropriate cholesterol, blood-pressure, diabetes and smoking care. Symptom improvement does not demonstrate that every future coronary risk has disappeared. NHS CABG clinical role and ongoing disease, July 3, 2025.
There is no financially screened supplement regimen here that opens a clinically important obstruction, keeps every graft or stent patent, or replaces the recommended procedure. A laboratory claim about circulation does not establish human outcomes.
Rehabilitation can support recovery with assessed activity and education. A walking or exercise programme should reflect the operation, symptoms, wound healing and other illnesses. Do not translate an average recovery timetable into permission for heavy lifting or unrestricted sport. NHS CABG recovery, July 3, 2025.
Mood changes, fatigue and anxiety can make recovery difficult. Tell the care team if distress interferes with sleep, activity or medicine use; support is part of follow-up rather than proof the procedure failed. NHLBI selected CABG follow-up context, March 24, 2022.
Comparing treatment goals, outcomes and recovery
The most useful comparison keeps the diagnosis and outcome consistent. Relief of angina, longer-term events, repeat treatment, wound recovery and medicine burden are different outcomes. A claim about one cannot automatically establish superiority on another.
PCI generally involves catheter access rather than the chest operation used in traditional CABG; that does not make it risk-free. CABG may involve chest and graft-harvest wounds and more extensive recovery support. The practical comparison should use the actual planned approaches, not a generic average. NHS PCI risk discussion, October 4, 2022; NHS CABG recovery, July 3, 2025.
Before consent, ask for the expected benefit, important complications, alternatives and uncertainty in understandable terms. If numbers are supplied, ask which population and time period they describe and whether they apply to the proposed procedure. NHLBI CABG preparation questions, March 24, 2022.
If chest symptoms recur after treatment, seek assessment. A previous successful procedure is not reassurance that new symptoms cannot be cardiac. The follow-up team should explain which symptoms require urgent help and who to contact for other concerns. GSTT post-angioplasty safety and follow-up, March 2026 version4.
Procedure complications and emergency symptoms
PCI risks include bleeding or vessel damage at the access site, reaction to contrast and serious complications such as heart attack or stroke. The actual risk depends on health and whether the procedure is planned or urgent. No numerical “small risk” guarantee is supplied. NHS PCI risk discussion, October 4, 2022.
CABG complications can include bleeding, infection, rhythm problems, kidney problems and heart attack or stroke. New confusion or memory problems also need appropriate assessment rather than an automatic promise that they resolve. Ask how the team assesses these risks in the proposed operation. NHS CABG complications and urgent symptoms, July 3, 2025.
Call the local emergency service for new persistent concerning chest pain, chest symptoms with sweating or breathlessness, stroke-like weakness/speech difficulty, collapse or severe breathing difficulty. Do not drive yourself or wait for a routine appointment. Previous PCI/CABG does not exclude another emergency. NHS CABG complications and urgent symptoms, July 3, 2025.
After discharge, worsening wound pain/redness, discharge, fever or new palpitations need prompt contact with the care team. Severe bleeding or serious deterioration requires emergency help. Report a cold or painful hand/foot after arterial access urgently; follow the specific discharge plan. GSTT post-angioplasty safety and follow-up, March 2026 version4.
Antiplatelets, other medicines and procedural coordination
Procedure planning includes antiplatelets, anticoagulants, diabetes medicines, pain medicines and supplements. Their names and purposes matter because they address different risks. The surgery and prescribing teams should coordinate any change, including a restart plan where needed. GSTT heart-surgery preparation, December 2023 version1.
After a stent, obtain the written antiplatelet plan and arrange repeat supplies. Do not stop because symptoms improve or because dental treatment is planned without involving the relevant clinicians. Fixed durations from an old general article are not a substitute for the discharge instructions. Leeds PCI discharge and medicine continuity, June 4, 2025.
Pain-treatment choices after an intervention should be checked against bleeding concerns, kidney health and other prescriptions. A supplement marketed for clotting or circulation also needs an ingredient-specific review. Bring actual packets or a current list to appointments. GSTT heart-surgery preparation, December 2023 version1.
Anatomy, health, allergies and clinical suitability
Suitability depends on artery anatomy and the overall clinical situation. Kidney/lung disease, frailty, previous operations and other illnesses can change preparation, procedure options or recovery needs. An educational list cannot decide that surgery is inappropriate or that PCI must be used. NHLBI selected CABG assessment framework, August 28, 2024.
Report prior reactions to contrast, anaesthetic or medicines, bleeding history, kidney concerns and every current prescription. The team can plan tests or precautions. Do not infer that a previous reaction means there is no possible treatment. NHS PCI risk discussion, October 4, 2022.
If pregnancy is possible, tell the team before tests or an intervention so that imaging, medicine and anaesthetic decisions can be assessed. There is no general permission or refusal rule here.
Someone awaiting a planned operation should contact the service if the condition worsens. Sudden serious deterioration needs emergency care rather than waiting for the scheduled admission. GSTT heart-surgery preparation, December 2023 version1.
Preparation, discharge, activity and follow-up
This guide contains no medicine dose, fasting time, home medication-stop protocol or fixed discharge/activity schedule. Use the actual instructions from the intervention team; clarify contradictory letters before the planned procedure. NHLBI CABG preparation questions, March 24, 2022.
Pre-assessment can review heart/lung/kidney health, medicines, allergies and practical needs. Confirm transport, support at home, wound care and how to obtain advice after discharge. The hospital’s specific pathway should be clear before the day of treatment. GSTT heart-surgery preparation, December 2023 version1.
Recovery differs after planned PCI, heart-attack PCI and CABG. Obtain advice about activity, work, sex, travel and driving based on the clinical situation and local rules. A typical number of days or weeks is not a clearance certificate. NHS CABG recovery, July 3, 2025.
Keep the discharge summary, current medicine list and follow-up details. Ask how symptoms, blood tests or imaging will be reviewed; no universal five-year surveillance test is recommended here. NHLBI selected CABG follow-up context, March 24, 2022.
Laboratory device findings versus human outcomes
Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Research funding at a glance
22 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The generic procedures have no single corporate owner; device makers, pharmaceutical producers and clinical providers have distinct commercial/service interests. National NHS and separate GSTT/Leeds provider finances, plus NHLBI budget/gift authority, were actually checked. Complete named contributor, specific source allocation and original device/drug/procedure-trial finance remains unresolved; no sponsored comparative outcome is used as independent proof.
The clinical indication is separate from the ownership of commercial device products. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS PCI overview, October 4, 2022, review overdue | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual October 4, 2022 body read with overdueOctober 2025 review. Stable catheter/stent mechanism and risk questions only; bare-metal/drug-eluting selection thresholds, fixed antiplatelet durations, thrombolysis/survival comparison, harmless-pain assurances, food/medicine/preparation and driving schedules excluded. Public-care accuracy incentive; contributor/original device-drug-trial finance unclosed. Role: Selected PCI meaning and planned/emergency distinction. |
| NHS PCI mechanism, October 4, 2022, selected context | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual October 4, 2022 body read with overdueOctober 2025 review. Stable catheter/stent mechanism and risk questions only; bare-metal/drug-eluting selection thresholds, fixed antiplatelet durations, thrombolysis/survival comparison, harmless-pain assurances, food/medicine/preparation and driving schedules excluded. Public-care accuracy incentive; contributor/original device-drug-trial finance unclosed. Role: Catheter/balloon/stent mechanism; dated drug/type/protocol rules excluded. |
| NHS PCI risk discussion, October 4, 2022 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual October 4, 2022 body read with overdueOctober 2025 review. Stable catheter/stent mechanism and risk questions only; bare-metal/drug-eluting selection thresholds, fixed antiplatelet durations, thrombolysis/survival comparison, harmless-pain assurances, food/medicine/preparation and driving schedules excluded. Public-care accuracy incentive; contributor/original device-drug-trial finance unclosed. Role: Access-vessel, bleeding, contrast and serious-event risks. |
| NHS CABG definition, July 3, 2025 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual July 3, 2025 original body read; selected definition, clinical questions, recovery and safety only. Public-care accuracy/accountability incentives; exact page allocation, contributor and original procedure/device/drug-trial finances unclosed. No independent comparative outcome, universal recovery/driving schedule or graft-number limit. Role: CABG definition and graft mechanism. |
| NHS CABG clinical role and ongoing disease, July 3, 2025 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual July 3, 2025 original body read; selected definition, clinical questions, recovery and safety only. Public-care accuracy/accountability incentives; exact page allocation, contributor and original procedure/device/drug-trial finances unclosed. No independent comparative outcome, universal recovery/driving schedule or graft-number limit. Role: Clinical purpose, planned/emergency use and disease-not-cured distinction. |
| NHS CABG operation context, July 3, 2025; media September 2026 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual July 3, 2025 original body read; selected definition, clinical questions, recovery and safety only. Public-care accuracy/accountability incentives; exact page allocation, contributor and original procedure/device/drug-trial finances unclosed. No independent comparative outcome, universal recovery/driving schedule or graft-number limit. Role: Anaesthesia, surgical graft/monitoring context; schedules/graft cap excluded. |
| NHS CABG recovery, July 3, 2025 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual July 3, 2025 original body read; selected definition, clinical questions, recovery and safety only. Public-care accuracy/accountability incentives; exact page allocation, contributor and original procedure/device/drug-trial finances unclosed. No independent comparative outcome, universal recovery/driving schedule or graft-number limit. Role: Wounds, activity, home support and rehabilitation context. |
| NHS CABG complications and urgent symptoms, July 3, 2025 | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual July 3, 2025 original body read; selected definition, clinical questions, recovery and safety only. Public-care accuracy/accountability incentives; exact page allocation, contributor and original procedure/device/drug-trial finances unclosed. No independent comparative outcome, universal recovery/driving schedule or graft-number limit. Role: Complications and emergency/wound/rhythm warning symptoms. Routine-resolution guarantees for rhythm, kidney or memory complications and automatic benefit-over-risk reassurance excluded. |
| NHLBI selected CABG assessment framework, August 28, 2024 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual 2022/2024 dated original body read; selected anatomy/team/preparation/technique/recovery context only. Standalone diabetes/arrest/heart-failure eligibility, blanket off-pump/minimally-invasive superiority, universal test-after5years, implant/rehabilitation/timing and comparative outcome claims excluded. Public accountability/accuracy incentives; complete author/page allocation and original device/drug/procedure-trial finance unclosed. Role: Team and complex-coronary anatomy discussion; standalone eligibility excluded. |
| NHLBI CABG preparation questions, March 24, 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual 2022/2024 dated original body read; selected anatomy/team/preparation/technique/recovery context only. Standalone diabetes/arrest/heart-failure eligibility, blanket off-pump/minimally-invasive superiority, universal test-after5years, implant/rehabilitation/timing and comparative outcome claims excluded. Public accountability/accuracy incentives; complete author/page allocation and original device/drug/procedure-trial finance unclosed. Role: Medicine, preparation and consent questions. |
| NHLBI CABG technique and risks, March 24, 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual 2022/2024 dated original body read; selected anatomy/team/preparation/technique/recovery context only. Standalone diabetes/arrest/heart-failure eligibility, blanket off-pump/minimally-invasive superiority, universal test-after5years, implant/rehabilitation/timing and comparative outcome claims excluded. Public accountability/accuracy incentives; complete author/page allocation and original device/drug/procedure-trial finance unclosed. Role: Technique choices and risk discussion; superiority excluded. |
| NHLBI selected CABG follow-up context, March 24, 2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual 2022/2024 dated original body read; selected anatomy/team/preparation/technique/recovery context only. Standalone diabetes/arrest/heart-failure eligibility, blanket off-pump/minimally-invasive superiority, universal test-after5years, implant/rehabilitation/timing and comparative outcome claims excluded. Public accountability/accuracy incentives; complete author/page allocation and original device/drug/procedure-trial finance unclosed. Role: Selected ongoing care and medicines; fixed surveillance schedule excluded. |
| GSTT heart-surgery preparation, December 2023 version1 | Guy’s and St Thomas’ NHS Foundation Trust: actual audited 2025–26 accounts discloses NHS commissioners, private patients, research/education, charitable and commercial income. Actual institutional partnership names include Johnson & Johnson Managed Services, Diaverum and ActiveCareGroup; no attribution to this leaflet or complete contributor/trial chain established. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | C provisional — actual December2023v1 preparation/CABG/risk/medicine/contact sections and reviewDecember 2026 read. Specialist provider accountability and service/research incentives; no complete individual contributor/underlying procedure-device-drug trial chain. Harmless graft-harvest, guaranteed angina elimination, all-CABG-at-main-surgery, numeric risks, stroke-recovery and extremely-rare-death guarantees excluded; clinical discussion/preparation only. Role: Actual preparation, medicine lists and deterioration context. |
| GSTT post-angioplasty safety and follow-up, March 2026 version4 | Guy’s and St Thomas’ NHS Foundation Trust: actual audited 2025–26 accounts discloses NHS commissioners, private patients, research/education, charitable and commercial income. Actual institutional partnership names include Johnson & Johnson Managed Services, Diaverum and ActiveCareGroup; no attribution to this leaflet or complete contributor/trial chain established. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | B provisional — actual March 2026 version4 original. Specialist provider accountability; selected wound/urgent symptoms, follow-up and contact context. Universal recovery/travel/driving intervals and fixed chest-pain wait excluded. Contributor/drug/device-study finance unclosed. Role: Actual March 2026 follow-up/wound safety; fixed chest-pain waits excluded. |
| Leeds PCI discharge and medicine continuity, June 4, 2025 | Separate NHS Trust: commissioner, private-patient, research/training and charitable routes. 2025–26 accounts. Page budget and author/trial financial chain unresolved. | United Kingdom; Leeds Teaching Hospitals NHS Trust, Leeds, England. Local specialist pathway; not national NHS website finance. | Tier 2 provider and charity/service routes, provisional; commercial research documented. | B provisional — actual June 4, 2025 reviewed original names Murugapathy Veerasamy, Hilary Copsey and Allison Romaniw. Specialist care accountability; medicine continuity and written discharge context only, no universal duration/activity/driving schedule. Contributor and underlying medicine/device-trial finance unresolved. Role: Post-stent medicine continuity and written discharge plan. |
| Guy’s and St Thomas’ audited 2025–26 accounts | Guy’s and St Thomas’ NHS Foundation Trust: actual audited 2025–26 accounts discloses NHS commissioners, private patients, research/education, charitable and commercial income. Actual institutional partnership names include Johnson & Johnson Managed Services, Diaverum and ActiveCareGroup; no attribution to this leaflet or complete contributor/trial chain established. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 3 institutional financial self-report. | B provisional — actual audited institutional report, no full individual allocation. Financial provenance only. |
| NHS England actual audited 2025–26 accounts | National NHS England: actual 2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| Leeds Teaching Hospitals audited 2025–26 accounts | Separate NHS Trust: commissioner, private-patient, research/training and charitable routes. 2025–26 accounts. Page budget and author/trial financial chain unresolved. | United Kingdom; Leeds Teaching Hospitals NHS Trust, Leeds, England. Local specialist pathway; not national NHS website finance. | Tier 3 institution financial/contact self-disclosure. | B provisional. Audited accounts and published institution location support provenance; clinical-page allocation, full sponsor chain and author independence not cleared. Financial provenance only. |
| Leeds 2026 annual report publication and institution location | Separate NHS Trust: commissioner, private-patient, research/training and charitable routes. 2025–26 accounts. Page budget and author/trial financial chain unresolved. | United Kingdom; Leeds Teaching Hospitals NHS Trust, Leeds, England. Local specialist pathway; not national NHS website finance. | Tier 3 institution financial/contact self-disclosure. | B provisional. Audited accounts and published institution location support provenance; clinical-page allocation, full sponsor chain and author independence not cleared. Financial provenance only. |
Frequently asked questions
What is the main difference? PCI opens from inside an artery; CABG creates a route around an obstruction.
Is a smaller incision always better? It does not establish the best overall option.
Does bypass cure coronary disease? No; ongoing care remains important.
Does every angiogram lead to a stent? No automatic intervention follows.
Can I stop antiplatelets after a successful stent? Follow the prescribing team’s written plan.
Should I wait for follow-up with serious new chest pain? No. Seek emergency assessment.
Sources and funding notes
- NHS PCI overview, October 4, 2022, review overdue — Selected PCI meaning and planned/emergency distinction.
- NHS PCI mechanism, October 4, 2022, selected context — Catheter/balloon/stent mechanism; dated drug/type/protocol rules excluded.
- NHS PCI risk discussion, October 4, 2022 — Access-vessel, bleeding, contrast and serious-event risks.
- NHS CABG definition, July 3, 2025 — CABG definition and graft mechanism.
- NHS CABG clinical role and ongoing disease, July 3, 2025 — Clinical purpose, planned/emergency use and disease-not-cured distinction.
- NHS CABG operation context, July 3, 2025; media September 2026 — Anaesthesia, surgical graft/monitoring context; schedules/graft cap excluded.
- NHS CABG recovery, July 3, 2025 — Wounds, activity, home support and rehabilitation context.
- NHS CABG complications and urgent symptoms, July 3, 2025 — Complications and emergency/wound/rhythm warning symptoms.
- NHLBI selected CABG assessment framework, August 28, 2024 — Team and complex-coronary anatomy discussion; standalone eligibility excluded.
- NHLBI CABG preparation questions, March 24, 2022 — Medicine, preparation and consent questions.
- NHLBI CABG technique and risks, March 24, 2022 — Technique choices and risk discussion; superiority excluded.
- NHLBI selected CABG follow-up context, March 24, 2022 — Selected ongoing care and medicines; fixed surveillance schedule excluded.
- GSTT heart-surgery preparation, December 2023 version1 — Actual preparation, medicine lists and deterioration context.
- GSTT post-angioplasty safety and follow-up, March 2026 version4 — Actual March 2026 follow-up/wound safety; fixed chest-pain waits excluded.
- Leeds PCI discharge and medicine continuity, June 4, 2025 — Post-stent medicine continuity and written discharge plan.
- Guy’s and St Thomas’ audited 2025–26 accounts — Financial provenance only.
- NHS England actual audited 2025–26 accounts — Financial provenance only.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- Leeds Teaching Hospitals audited 2025–26 accounts — Financial provenance only.
- Leeds 2026 annual report publication and institution location — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Actual NHS PCIoverview/how/risksOctober4, 2022 bodies read; nextreviewOctober2025overdue. Stenttype thresholds/fixed antiplatelet schedules, thrombolysis-survival comparison, harmlesspain/extraheartbeatassurances, universal preparation/driving timings excluded. Actual NHS CABG fiveJuly3, 2025 originals read; how-page mediaSept2026date nottreated as fullclinicalreview. Graft-numbercap, universal recovery/activity/driving and automaticriskbenefit/resolution guarantees excluded. Actual NHLBI CABGwhoAugust28, 2024 and prepare/during/recoveryMarch24, 2022 bodies read; no standaloneeligibility, off-pump/robot/hybrid superiority, universal5yearsurveillance or numericaloutcomes. Actual GSTTDecember2023v1 preparation/CABG/risk/medicine/contact passages read; harmlessharvest, allCABGcombinedoperation, guaranteedanginaelimination, numericrisk/strokerecovery/deathassurances excluded. Actual GSTTPCIaftercareMarch2026v4 and LeedsPCIJune4, 2025 namedoriginals read inthisrun; no fixedpainwait or drugduration. Actual NHS/GSTT/Leeds 2025–26finance andNHLBIbudget/gift checkedpreviously. Complete author/originalcomparativetrialchainunclosed; clinicalcontextonly. No home treatmentselection, doses, stop/fasting protocol, independentwinner or procedureoutcomepromise. Leeds Teaching Hospitals 2025–26 original audited accounts were read separately from national NHS policy. Clinical leaflet review dates are source-specific and do not establish that every cited study was updated. Local procedure rates, fixed antithrombotic doses and recovery promises are not imported as independent evidence or personal instructions. Public clinical sources concentrate on US and English services; referral and treatment availability vary by jurisdiction. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.